Repurposing CD8 + T cell immunity against SARS-CoV-2 for cancer immunotherapy: a positive aspect of the COVID-19 pandemic?
JSON
Gujar S, Pol JG, Kim Y, Kroemer G
Oncoimmunology 9 (1) 1794424 [2020-07-16; online 2020-07-16]
The COVID-19 pandemic has afflicted most countries on the planet. As a result, immunity against SARS-CoV-2, induced via natural infections or imminent vaccinations, is expected to develop in a large fraction of the global population. Here, we propose to exploit SARS-CoV-2-specific CD8 + T cells for cancer immunotherapy strategies.
PubMed 32923158
DOI 10.1080/2162402X.2020.1794424
Crossref 10.1080/2162402X.2020.1794424
pii: 1794424
pmc: PMC7458627